In Bristol-Myers Squibb Co (NYSE:BMY), Orbimed Advisors revealed holding 7.19 million shares, worth nearly $349 million. The stake represents an increase from 5.97 million shares the fund reported previously.
Deutsche Bank initiated coverage on Bristol-Myers Squibb Co. (NYSE: BMY) with a Hold rating and a price target of $52.00. Analyst Gregg Gilbert said, "We are initiating coverage of Bristol Myers Squibb (BMY) with a Hold rating and $52 target price.
In our new rank based on the most recent short interest data from NASDAQ, Bristol-Myers Squibb Co. (NYSE: BMY) has taken over the position of #111 most shorted S&P 500 component, from Vulcan Materials Co (NYSE: VMC) which is now in the #220 spot.
On 20 AUG Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq: CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of ...
Bristol-Myers Squibb Co. (BMY) announced yesterday that the European Commission (EC) has granted approval for the use of Daklinza, a drug developed for the treatment of the fatal Chronic Hepatitis C Virus (HCV) infection in adults.
Allied Minds PLC (ALM.L) and Bristol-Myers Squibb Co.(BMY: Quote) has agreed to form a jointly owned new company called Allied-Bristol Life Sciences LLC, for translating early-stage academic innovation to therapeutic candidates for clinical study.